Breaking News Instant updates and real-time market news.

CBM

Cambrex

$46.23

-0.375 (-0.80%)

, CTLT

Catalent

$41.84

0.69 (1.68%)

04:55
06/20/18
06/20
04:55
06/20/18
04:55

Stephens to hold a bus tour

Mid-Atlantic Healthcare Bus Tour travels throughout New Jersey and Pennsylvania to meet with healthcare companies on June 19-20.

CBM

Cambrex

$46.23

-0.375 (-0.80%)

CTLT

Catalent

$41.84

0.69 (1.68%)

OSUR

OraSure

$17.71

0.08 (0.45%)

GEN

Genesis Healthcare

$2.66

-0.19 (-6.67%)

HCSG

Healthcare Services

$42.01

-0.26 (-0.62%)

UHS

Universal Health

$115.09

-0.1 (-0.09%)

WST

West Pharmaceutical

$101.66

0.17 (0.17%)

  • 20

    Jun

  • 26

    Jun

CBM Cambrex
$46.23

-0.375 (-0.80%)

02/14/18
LBOW
02/14/18
DOWNGRADE
LBOW
Neutral
Cambrex downgraded to Neutral from Buy at Longbow
01/16/18
01/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Axalta Coating (AXTA) resumed with an Underperform at BofA/Merrill. 2. UBS (UBS) and Credit Suisse (CS) were initiated with an Underweight at Barclays. 3. Nutrien (NTR) initiated with a Neutral at Goldman Sachs. 4. Cambrex (CBM) initiated with an Outperform at William Blair. 5. Dicerna (DRNA) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/18
WBLR
01/16/18
INITIATION
WBLR
Outperform
Cambrex initiated with an Outperform at William Blair
William Blair started Cambrex with an Outperform rating saying the company offers an "excellent way" for smaller-capitalization investors to participate in the pharma outsourcing trend.
10/31/17
CHLM
10/31/17
NO CHANGE
Target $60
CHLM
Buy
Cambrex price target lowered to $60 from $70 at Craig-Hallum
Craig-Hallum analyst Matt Hewitt lowered his price target for Cambrex (CBM) to $60 from $70 following last week's Q3 report by partner Gilead Sciences (GILD). Via the report, Gilead disclosed that total HCV product sales declined about 34% which coincided with about 26% less year over year patient initiations worldwide. The analyst reiterates a Buy rating on Cambrex's shares.
CTLT Catalent
$41.84

0.69 (1.68%)

03/21/18
03/21/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Myriad Genetics (MYGN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Steve Beuchaw citing share price underperformance and improving cancer testing survey share trends. 2. FedEx (FDX) upgraded to Buy from Hold at Stifel with analyst David Ross saying he likes the company's "general earnings trajectory" following third quarter results. 3. Children's Place (PLCE) upgraded to Buy from Neutral at Citi with analyst Kate McShane saying the company reported another quarter of industry leading comps. 4. Catalent (CTLT) upgraded to Outperform from Market Perform at Raymond James with analyst Michael Baker saying shares are down 15% following the first quarter report on tough second half 2018 comps, and believes shares reflect this dynamic now. 5. WellCare (WCG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Peter Costa saying he believes WellCare could benefit from significantly higher favorable prior period development in 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/28/18
03/28/18
UPGRADE
Target $48

Overweight
Catalent upgraded to Overweight at KeyBanc
As previously reported, KeyBanc analyst Donald Hooker upgraded Catalent to Overweight from Sector Weight, with a $48 price target, ahead of what he expects will be an increasing flow of new drug approvals in the coming years, as well as a rising prevalence of "value-based contracts" in which drug companies are held financially accountable for the real-world impact of their therapies.
03/28/18
KEYB
03/28/18
UPGRADE
KEYB
Overweight
Catalent upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Matthew Mishan upgraded Catalent to Overweight with a $48 price target.
03/26/18
WBLR
03/26/18
NO CHANGE
WBLR
Outperform
William Blair sees Biohaven safety as 'strong differentiator' versus Allergan
William Blair analyst Tim Lugo believes Biohaven Pharmaceutical's (BHVN) Phase III data this morning confirmed rimegepant's efficacy and "clean" safety profile. The analyst keeps an Outperform rating on the shares, which are trading down 29%, or $7.12, to $17.64. Lugo understands the focus on comparing today's results with the recent ubrogepant Phase III data from Allergan (AGN), but he notes that comparisons are complicated as Biohaven did not allow rescue medications or re-dosing. While the efficacy in Study 302 looked in line with Allergan's ubrogepant Phase III study, Study 301 looked to be affected by a higher placebo rate of a few percentage points, which negatively affected the difference versus placebo, Lugo tells investors in a research note. He believes safety for rimegepant is "impressive" and likely a " William Blair sees Biohaven safety as 'strong differentiator' versus AllerganWhile a drop-off in efficacy between Phase II and Phase III results is common, it may have been exacerbated as management noted the rimegepant formulation in the Phase III took 30 minutes longer to reach serum maximal concentration than the formulation used in Phase II, Lugo points out. Further, he thinks the profile of rimegepant could be boosted by the company's Phase III trial of a rapidly dissolving sublingual rimegepant formulation using Catalent's (CTLT) Zydis technology, which the analyst says should lead to a faster bioavailability.
OSUR OraSure
$17.71

0.08 (0.45%)

05/04/18
ADAM
05/04/18
NO CHANGE
Target $20
ADAM
Buy
OraSure selloff looks overdone, says Canaccord
Canaccord analyst Mark Massaro noted OraSure shares traded down following its Q1 beat. The analyst thinks the weakness is overblown as he notes molecular collections grew revenues 72% year-over-year and continues to win new business in a huge market. He also noted the leadership changes and the ongoing strategic review. Massaro maintained his Buy rating and lowered his price target to $20 from $24 on OraSure shares.
11/22/17
JEFF
11/22/17
NO CHANGE
JEFF
Hold
Jefferies unclear how much of 'eye-catching' OraSure contract is incremental
Jefferies analyst Brandon Couillard said the size of the $143M contract announced by OraSure was "eye-catching," but that it is still unclear how much of this is truly incremental to the current run-rate with the customer in question. The analyst, who said his "best guess" and current assumption is that the contract is with 23&Me, maintains a Hold rating on OraSure shares.
11/22/17
ADAM
11/22/17
NO CHANGE
Target $21
ADAM
Buy
OraSure contract win bigger than full year revenues, says Canaccord
Canaccord analyst Mark Massaro noted OraSure won a massive $143M contract to supply its market-leading Oragene Dx saliva collection device to a leading generics customer. The analyst said the contract win is bigger than its previous year revenue number and indicates the direct-to-consumer genomics business is booming. Massaro reiterated his Buy rating and raised his price target to $21 from $19 on OraSure shares.
11/21/17
KING
11/21/17
NO CHANGE
Target $19
KING
Buy
OraSure signs $143M deal, likely with 23andMe, says CL King
OraSure announced it signed a $143M deal with a consumer genomics company. CL King analyst David Westenberg believes the company is likely 23andme and views it as a positive as it indicates the initial $20M deal its signed with the company in April has been fulfilled significantly earlier than expected. The analyst believes Orasure's exposure to the consumer genomics market provides significant upside to estimates. Westenberg rates OraSure a Buy with a $19 price target.
GEN Genesis Healthcare
$2.66

-0.19 (-6.67%)

07/05/17
CANT
07/05/17
INITIATION
Target $7
CANT
Overweight
Genesis Healthcare initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Joseph France started Genesis Healthcare with an Overweight rating and $7 price target.
02/26/18
RBCM
02/26/18
NO CHANGE
Target $62
RBCM
Sector Perform
Welltower price target lowered to $62 from $72 at RBC Capital
RBC Capital analyst Michael Carroll lowered his price target on Welltower (HCN) to $62, stating that the company's earnings growth will be constrained by asset sales and its deal to reduce rent on its master lease with Genesis Healthcare (GEN). Carroll says that in the longer term, the Genesis rent agreement will strengthen its tenant's credit profile, but still remains "cautious on the skilled nursing facility space in general given the ongoing evolution of the reimbursement model". The analyst keeps his Sector Perform rating on Welltower.
HCSG Healthcare Services
$42.01

-0.26 (-0.62%)

06/06/18
WBLR
06/06/18
UPGRADE
WBLR
Outperform
Healthcare Services upgraded to Outperform from Market Perform at William Blair
William Blair analyst Ryan Daniels upgraded Healthcare Services Group to Outperform. The analyst sees an attractive long-term investment opportunity at current share levels.
04/18/18
FBCO
04/18/18
NO CHANGE
Target $48
FBCO
Outperform
Healthcare Services price target lowered to $48 from $62 at Credit Suisse
Credit Suisse analyst A.J. Rice lowered his price target for Healthcare Services to $48 from $62 following mixed results in Q1. The analyst reiterates an Outperform rating on the shares.
04/18/18
04/18/18
DOWNGRADE
Target $44

Hold
Healthcare Services downgraded to Hold with $44 price target at Stifel
As previously reported, Stifel analyst Chad Vanacore downgraded Healthcare Services to Hold from Buy, noting the risk he sees that credit quality deterioration in the company's base of skilled nursing clients could keep shares range-bound in the near-term. He also lowered his 2018 estimates, largely to account for fewer new contract additions early in the year as the company shifts some of its focus to collections rather than selling. Vanacore cut his price target on Healthcare Services to $44 from $57.
06/12/18
BNCH
06/12/18
INITIATION
Target $50
BNCH
Buy
Healthcare Services initiated with a Buy at Benchmark
Benchmark started Healthcare Services Group with a Buy rating and $50 price target.
UHS Universal Health
$115.09

-0.1 (-0.09%)

03/06/18
BARD
03/06/18
NO CHANGE
Target $140
BARD
Outperform
Universal Health price target raised to $140 from $122 at Baird
Baird analyst Whit Mayo raised his price target on Universal Health to $140 from $122 following good Q4 results. The analyst said the results were underpinned by incredibly strong acute growth and improved health plan trends. He noted improved guidance and a clear inflection with the behavioral health side. Mayo reiterated his Outperform rating on Universal Health shares.
03/05/18
FBCO
03/05/18
NO CHANGE
Target $140
FBCO
Outperform
Universal Health price target raised to $140 from $135 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Universal Health to $140 from $135 on valuation. The analyst reiterates an Outperform rating on the shares.
01/30/18
WELS
01/30/18
INITIATION
Target $144
WELS
Outperform
Universal Health resumed with an Outperform at Wells Fargo
Wells Fargo analyst Peter Costa resumed coverage of Universal Health Services with an Outperform rating and $144 price target. The company's "consistency and management skills" should allow it to trade at premium, the analyst contends.
05/09/18
MZHO
05/09/18
NO CHANGE
Target $35
MZHO
Buy
Tenet price target raised to $35 from $29 at Mizuho
Mizuho analyst Ann Hynes raised her price target for Tenet Healthcare (THC) to $35 as part of her Hospital model updates following the Q1 earnings season. The analyst reiterates a Buy rating on the shares. She also keeps Buy ratings on HCA Healthcare (HCA) and Universal Health (UHS).
WST West Pharmaceutical
$101.66

0.17 (0.17%)

10/17/17
BOFA
10/17/17
DOWNGRADE
BOFA
Neutral
West Pharmaceutical downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Derik De Bruin downgraded West Pharmaceuticals to Neutral and trimmed his price target to $98 from $100. The analyst sees limited upside to estimates and believes shares could be range bound over the next 12 months due to ongoing end market headwinds. De Bruin said several of West's customers have been impacted by recent hurricanes and are being impacted by inventory destocking.
04/25/18
BOFA
04/25/18
DOWNGRADE
BOFA
Underperform
West Pharmaceutical downgraded to Underperform from Neutral at BofA/Merrill
04/25/18
BOFA
04/25/18
DOWNGRADE
Target $85
BOFA
Underperform
West Pharmaceutical downgraded to Underperform on reduced growth at BofA/Merrill
As previously reported, BofA/Merrill downgraded West Pharmaceutical to Underperform from Neutral and lowered its price target to $85 from $100. Analyst Derik de Bruin said the company is experiencing ongoing customer inventory issues and mixed endmarkets, resulting a less attractive core growth and margin profile. The analyst views valuation as "more than full" and less deserving of a premium multiple relative to peers.
01/24/18
GSCO
01/24/18
INITIATION
Target $110
GSCO
Neutral
West Pharmaceutical initiated with a Neutral at Goldman Sachs
Goldman analyst Dana Flanders initiated West Pharmaceutical with a Neutral and $110 price target.

TODAY'S FREE FLY STORIES

MA

MasterCard

$204.52

(0.00%)

09:40
10/23/18
10/23
09:40
10/23/18
09:40
Options
Unusually active option classes on open October 23rd »

Unusual total active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

HON

Honeywell

$152.63

-0.86 (-0.56%)

09:39
10/23/18
10/23
09:39
10/23/18
09:39
Upgrade
Honeywell rating change  »

Honeywell upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QTS

QTS Realty Trust

$40.40

-0.59 (-1.44%)

09:39
10/23/18
10/23
09:39
10/23/18
09:39
Upgrade
QTS Realty Trust rating change  »

QTS Realty Trust upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 07

    Nov

EXPI

eXp World Holdings

$12.50

0.35 (2.88%)

09:39
10/23/18
10/23
09:39
10/23/18
09:39
Hot Stocks
eXp Realty to acquire ShowMeNow, terms not disclosed »

eXp Realty, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

TSLA

Tesla

$261.03

0.97 (0.37%)

09:38
10/23/18
10/23
09:38
10/23/18
09:38
Periodicals
Breaking Periodicals news story on Tesla »

Citron says long Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 29

    Oct

  • 13

    Dec

KOF

Coca-Cola Femsa

$59.41

-1.75 (-2.86%)

09:36
10/23/18
10/23
09:36
10/23/18
09:36
Upgrade
Coca-Cola Femsa rating change  »

Coca-Cola Femsa upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$47.93

0.34 (0.71%)

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Oracle initiated  »

Oracle initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Conference/Events
JPMorgan European & EMEA analysts to hold analyst/industry conference call »

European Utilities…

ABBV

AbbVie

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
AbbVie initiated  »

AbbVie initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

SNY

Sanofi

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Sanofi initiated  »

Sanofi reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

RHHBY

Roche

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Roche initiated  »

Roche reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 24

    Dec

09:35
10/23/18
10/23
09:35
10/23/18
09:35
General news
Treasury 2-year auction outlook: the $38 B 2-year sale »

Treasury 2-year auction…

PFE

Pfizer

$44.37

-0.13 (-0.29%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Pfizer initiated  »

Pfizer reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

GSK

GlaxoSmithKline

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 07

    Nov

LLY

Eli Lilly

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Eli Lilly initiated  »

Eli Lilly reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

NVS

Novartis

$87.12

-0.07 (-0.08%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Novartis initiated  »

Novartis reinitiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MRK

Merck

$72.56

0.22 (0.30%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Merck initiated  »

Merck reinitiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$50.87

-3.44 (-6.33%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Bristol-Myers initiated  »

Bristol-Myers reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 20

    May

AZN

AstraZeneca

$39.50

0.295 (0.75%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
AstraZeneca initiated  »

AstraZeneca reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Nov

MLCO

Melco Resorts & Entertainment

$17.74

-0.04 (-0.22%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Downgrade
Melco Resorts & Entertainment rating change  »

Melco Resorts &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

, BAC

Bank of America

$27.36

-0.95 (-3.36%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Technical Analysis
Technical Take: Bank of America drops in early trading »

The shares were last down…

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

BAC

Bank of America

$27.36

-0.95 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

UTX

United Technologies

$126.42

-2.22 (-1.73%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Hot Stocks
United Technologies says geo-political outlook is the biggest concern »

Says tariffs present a 5c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UBS

UBS

$13.77

-0.085 (-0.61%)

09:32
10/23/18
10/23
09:32
10/23/18
09:32
Periodicals
UBS backs down warning to staff about traveling to China, FT reports »

UBS has rescinded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$12.50

0.35 (2.88%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
eXp Realty to acquire ShowMeNow, terms not disclosed »

eXp Realty, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
Harley-Davidson says FY18 shipments will finish at low-end of guidance range »

Management says adapting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.